Real-World Studies
Olaparib Shows Real-World Activity After CDK4/6 Therapy in Breast Cancer Cohort
Gökdere et alTargeted Oncology

A multicenter retrospective study conducted by the Turkish Oncology Group (TOG) evaluated the real-world efficacy, sequencing, and safety of olaparib in 52 patients across 28 institutions with germline BRCA1/2-mutated hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer who had received prior cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor plus endocrine therapy.
At olaparib initiation, the median patient age was 49.9 years (interquartile range, 40.2–59.0 years). Over a median follow-up of 12.84 months (95% CI, 10.52–15.15), the objective response rate (ORR) was 57.7%, median progression-free survival (PFS) was 11.0 months (95% CI, 5.94–16.05), and the 12-month overall survival rate reached 78.7%.
Treatment sequencing analysis indicated that immediate olaparib therapy following CDK4/6 inhibition resulted in a numerically longer median PFS compared to sequencing after intervening systemic therapy (13.4 vs. 8.4 months), though this difference was not statistically significant (p = 0.088). Furthermore, earlier-line administration (defined as third line or earlier) was associated with longer PFS than later-line administration (fourth line or later) at 17.7 vs. 8.4 months (p = 0.005). Olaparib demonstrated clinically meaningful activity with manageable safety and no unexpected safety signals, though the nonrandomized sequencing observations require prospective validation.
Key Takeaways
- Olaparib achieved an objective response rate of 57.7%, a median progression-free survival of 11.0 months (95% CI, 5.94–16.05), and a 12-month overall survival rate of 78.7% after prior CDK4/6 inhibitor plus endocrine therapy.
- Earlier-line olaparib administration (≤ third line) was associated with longer median progression-free survival compared with later-line administration (≥ fourth line) at 17.7 versus 8.4 months (p = 0.005).
- Immediate post-CDK4/6 inhibitor olaparib sequencing showed a numerically longer median progression-free survival than use after intervening systemic treatment (13.4 versus 8.4 months; p = 0.088), with no unexpected safety signals observed.
Read the original sourceTargeted Oncology
